Eisai's Q1 revenue boosted by upfront payment from elacestrant deal
02 Aug 2023
Financial StatementVolume-Based ProcurementBiosimilarASHPost-Marketing Study
Headline results for the first quarter:
Revenue: JPY 197 billion ($1.4 billion), up 6.9%
Profit: JPY 20.9 billion ($146 million), down 25.3%
Note: All changes are versus the prior-year period unless otherwise stated
What the company said:
Eisai noted that revenue increased in the first quarter mainly due to the receipt of an $85-million upfront payment after transferring all future economic rights for the selective oestrogen receptor degrader elacestrant to DRI Healthcare. The company added that quarterly results also benefited from continued growth of Lenvima and Dayvigo.
Other results:
Oncology sales: JPY 82.4 billion, up 3.4%
Lenvima/Kisplyx: JPY 70.8 billion, up 6.7%
Halaven: JPY 9.5 billion, down 14.9%
Neurology sales: JPY 36.7 billion, down 1.1%
Dayvigo: JPY 9.4 billion, up 44.6%
Fycompa: JPY 8.1 billion, down 18.3%
Aricept: JPY 6.2 billion, down 1.6%
Looking ahead:
Eisai continues to project sales of JPY 712 billion ($5 billion) for fiscal 2023, down 4.4% from the previous fiscal year, while profit is forecast to decline 31.4% to JPY 39 billion ($273 million).
($1 = JPY 142.738)
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.